Navigation Links
Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
Date:9/25/2008

The in vivo results of QPI-1007 mark a new era for Quark. We can now rely solely on internally-developed novel compositions and proprietary siRNA structures to develop products that have the potential to provide greater efficacy than current treatments. The breadth of our new structures allows us to selectively pick the most efficacious, stable siRNA structure, which is the most suitable for the specific sequence."

Dr. Logan stated, "QPI-1007 displayed significant neuroprotective activity compared to untreated controls and two different control siRNA molecules in our in vivo model. These results are very exiting. They show that QPI-1007 is a promising drug for ocular neuroprotection."

Dr. Di Polo commented, "The characteristic visual field changes and loss of vision in glaucoma are caused by the selective degeneration of retinal ganglion cells. Our results suggest that QPI-1007 may be an effective neuroprotective therapy for retinal ganglion cells in acute injuries such as non-artheritic ischemic optic neuropathy, and also in slow-progressing chronic optic nerve injuries such as glaucoma. QPI-1007 has the potential to serve an unmet medical need for these indications."

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel therapeutic RNAi drug candidates. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability to deliver siRNA non invasively to target tissues including the eye, ear, kidney, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified, siRNA molecule to inhibit the expression of the gene RTP801, licensed to Pfizer. In
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 Ardelyx, Inc. (NASDAQ: ARDX ... gastrointestinal, and metabolic diseases, today announced that a ... Stage 3 chronic kidney disease patients with type ... the primary endpoint of decreasing the urinary albumin-creatinine ... placebo. Ardelyx formed a partnership ...
(Date:5/5/2015)... , May 5, 2015 /CNW Telbec/ - ... Laval and known under the « ... the closing of the transaction previously announced on April ... issued and outstanding  shares of Orthoconcept (2008) inc.   ... 500 000 common shares (TSXV: ERG) to the vending ...
(Date:5/5/2015)... -- The preclinical contract research organization Absorption Systems , ... safety testing of medical devices, announces that Dr. ... at this week,s annual meeting of The Association for ... Denver, CO. The title of Dr. Gum,s ... Bio-Absorbable Carboxymethyl Hyaluronic Acid (CMHA) Polymer in a Rabbit ...
Breaking Medicine Technology:Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 2Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 3Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 4Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 5Ardelyx Reports Results from Phase 2a Clinical Trial Evaluating Tenapanor in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus and Albuminuria 6Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 2Ergoresearch announces closing of the acquisition of 49% of the shares of Orthoconcept (2008) inc. 3Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 2Dr. Glen Gum of Absorption Systems Presents at The Association for Research in Vision and Ophthalmology (ARVO) Meeting 3
... The U.S. Food and Drug Administration today approved Kalydeco ... fibrosis (CF) in patients ages 6 years and older who ... Regulator (CFTR) gene. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... lungs and other organs that ultimately leads to an early ...
... (OTCBB: VYST), the exclusive creator of Vytex® Natural Rubber ... first Chinese patent for its all-natural raw material. The company ... US and abroad that relate to Vytex NRL, with more ... ) The new US patent expands the claims ...
Cached Medicine Technology:FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis 2FDA Approves Kalydeco to Treat Rare Form of Cystic Fibrosis 3Vystar® Corporation Receives its Third US Patent and First Chinese Patent for Vytex® Natural Rubber Latex 2Vystar® Corporation Receives its Third US Patent and First Chinese Patent for Vytex® Natural Rubber Latex 3
(Date:5/5/2015)... 05, 2015 “Given that Hispanics are one ... the CDC report are a major step in the arsenal ... everyone. For the past 30 years, data have accumulated that ... Today we see the urgency and the need to create ... health outcomes for all,” said Jane L. Delgado, PhD, MS, ...
(Date:5/5/2015)... 2015 The global lab automation market ... $3,474.2 Million in 2014, at an estimated CAGR of ... lab automation market on the basis of equipment and ... On the basis of application, Lab Automation Market is ... proteomics solutions. Drug discovery is a major application of ...
(Date:5/5/2015)... The newly minted Regan Arts has just released a unique self-help ... from his 20 years working in the field of wilderness therapy. ... a parenting book and why this one, she replied, “What resonates ... it is a journey, not a destination...that the question is not ... together and sometimes not...that each of our struggles is unique. What ...
(Date:5/5/2015)... Georgia (PRWEB) May 05, 2015 ... of Victoria BC announced the Skedans Sensor Collaboration ... platform, for mobile and web app developers, provides tooling ... airborne and mobile sensors. , The Skedans Sensor Collaboration ... the intersection of the Internet of Things, Web Real ...
(Date:5/5/2015)... Information Innovators Inc. ... federal government, today announced its acquisition of ... solutions exclusively to federal government customers through its ... security, health services, and program management support. The ... as a Third Party Assessment Organization (3PAO) for ...
Breaking Medicine News(10 mins):Health News:“Its about time,” Declares the National Alliance for Hispanic Health on First CDC Study of Hispanic Health 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 5Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 2Health News:The Last Parenting Book You Will Ever Need: Veteran Publisher Judith Regan Releases A Provocative New Book By Dr. Brad Reedy, "The Journey Of The Heroic Parent" 3Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 2Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 3Health News:Information Innovators Inc. (Triple-i) Acquires Leading Cyber Security and Health-Focused Solutions Company, Creative Computing Solutions, Inc. 4
... make you less upset about making errors, according to ... a journal of the Association for Psychological Science. The ... distress-response while participants made mistakes on a test. Those ... less prominent response to mistakes than those who hadn,t. ...
... them to investigate, for the first time, how human testes ... Until now it has been impossible to study testicular development ... to understand the processes that can lead to the onset ... and how factors, such as common environmental chemicals, might play ...
... By Steven Reinberg HealthDay Reporter , TUESDAY, ... As of 2009, almost 3 in every 10 adults ... in 2007, according to a new government report released Tuesday. ... Disease Control and Prevention (CDC), also found that between 2007-2009, ...
... Project, joined by major consumer, physician and chemical manufacturer ... would give the U.S. Food and Drug Administration (FDA) ... organizations made the announcement in a joint letter to ... Michael Bennet (D-CO), who will introduce this drug safety ...
... all-over tan may be impossible to achieve because some body ... study has found. Researchers - funded by the Medical ... the results explain why some holidaymakers find it so hard ... The findings, published in the journal Experimental Dermatology , ...
... big impact on the food you eat, the clothes you ... in a special section on Culture and Psychology in ... for Psychological Science, psychological scientists Denise C. Park from the ... University of Illinois at Urbana-Champaign discuss ways in which brain ...
Cached Medicine News:Health News:Brain study shows that thinking about God reduces distress -- but only for believers 2Health News:Scientists develop the first model for investigating the origins of testicular cancer in humans 2Health News:Number of Obese Adults Keeps Rising, CDC Says 2Health News:Number of Obese Adults Keeps Rising, CDC Says 3Health News:Consumer and manufacturing groups back bill to protect US drug supply 2Health News:Consumer and manufacturing groups back bill to protect US drug supply 3Health News:All-over tan is a myth, study finds 2Health News:Culture wires the brain: A cognitive neuroscience perspective 2
A fluorogenic enzyme-linked immunoassay (ELISA) for the quantitative measurement of myoglobin in human serum or plasma aiding in the diagnosis of acute myocardial infarction (AMI). Features : Dry che...
The Acute Care myoglobin method is an in vitro diagnostic test for the measurement of myoglobin in heparinized whole blood /plasma. Myoglobin measurements can be used as an aid in diagnosing myocardi...
... The VITROS ECi brings true automation ... immunodiagnostic testing. Highly sensitive assays for ... and bone metabolism testing are currently ... development. The VITROS ECi can simultaneously ...
IRMA kit for detection of the cardiac marker Myoglobin...
Medicine Products: